Pharmesis International Ltd.

BFK

SG1BH6000003

Pharmaceuticals

Market Closed - Singapore S.E. Other stock markets 03:14:16 2024-06-25 EDT			5-day change	1st Jan Change
0.081 ^SGD	-23.58%		-23.58%	-17.35%

06-14	Singapore Shares Down Tracking Global Market Losses; Soilbuild Soars 147%	MT
06-14	Pharmesis International Completes Subscription Deal Following Share Issue; Shares Surge 32%	MT

Pharmesis International Ltd. Appoints Chung Chia-Jung as Non-Independent Non-Executive Director and Member of the Audit Committee

December 15, 2017 at 04:08 am

Pharmesis International Ltd. announced the appointment of Chung Chia-Jung as Non-Independent Non-Executive Director and a member of the Audit Committee effective from December 15, 2017. From January 2014 to present Chung is a Project Manager of Chigin Metal Enterprise Co.,Ltd and from August 2013 to December 2013 Chung was a Project Coordinator of TMS Global Survey Services.

Latest news about Pharmesis International Ltd.

Singapore Shares Down Tracking Global Market Losses; Soilbuild Soars 147%	06-14	MT
Pharmesis International Completes Subscription Deal Following Share Issue; Shares Surge 32%	06-14	MT
Pharmesis International Secures Approval for Listing of Over 4 Million Shares	06-05	MT
Pharmesis International Ltd. Announces Board Appointment and Changes to the Composition of the Board and Board Committees	05-31	CI
Pharmesis International Enters Subscription Agreement for 4.1 Million Additional Shares	05-28	MT
Pharmesis to Issue 4 Million New Shares Under Placement	05-28	MT
Pharmesis International Ltd. Approves the Appointment of Seow Yong Teng as Lead Independent Director	04-30	CI
Pharmesis International Ltd. Announces Re-Designation of Chew Heng Ching to Non-Independent Non-Executive Chairman	04-30	CI
Pharmesis International Ltd. Announces Retirement of Lin Yimin as Member of Audit Committee	04-29	CI
Pharmesis’ Attributable Loss for 2023 Widens	04-14	MT
Pharmesis International Ltd. Announces the Retirement of Ms. Lin Yimin as a Director	04-14	CI
Pharmesis Launches New Product Line	03-26	MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months and Full Year Ended 31 December 2023	02-28	CI
Pharmesis International Ltd. Announces Changes to the Composition of the Board and Board Committees	23-09-29	CI
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Pharmesis International Flags Losses for H1	23-08-09	MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	23-08-08	CI
Pharmesis International Ltd. Announces Management Resignations	23-07-31	CI
Pharmesis International Ltd. Appoints Lin Yimin as Non-Independent Non-Executive Director and A Member of Audit Committee	23-07-31	CI
Pharmesis International Ltd. Announces Temporary Work Stoppages at its Manufacturing Facilities Located in Gulin County, Luzhou City, Sichuan Province	23-07-27	CI
Pharmesis International Issues 4.6 Million Shares to Two Subscribers	23-04-05	MT
Pharmesis International Gets Regulatory Nod to List 4.6 Million Shares	23-03-29	MT
Pharmesis International to Issue 4.6 Million Shares to Two Subscribers	23-03-21	MT
Pharmesis International Expects Loss in H2, FY22	23-02-28	MT

Chart Pharmesis International Ltd.

Duration

Period

More charts

Company Profile

Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMESIS INTERNATIONAL LTD.	-17.35%	1.89M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B